Host genetic determinants of HIV pathogenesis: An immunologic perspective

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 342-348

  Hunt, Peter W ^a,c   Carrington, Mary ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAIC FREDERICK INC   (United States)

^c Building 80 ^*  (United States)

Author keywords

CCR5; HIV pathogenesis; HLA; Host genetic variation; KIR

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR6; HLA A ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; VACCINE;

ADAPTIVE IMMUNITY; ALLELE; DISEASE COURSE; DRUG DESIGN; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; HEREDITY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION SENSITIVITY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS REPLICATION;

EID: 42049092144     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282fbaa92     Document Type: Review

References (58)

1. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947. This study reported the first genome-wide analysis of host polymorphisms associated with the control of HIV replication and disease progression, identifying at least two previously unrecognized potential host determinants of HIV pathogenesis.
2. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440.
3. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434.
4. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740. This study demonstrated that inhibitory KIR allotypes in the presence of their cognate HLA class I alleles are associated with both improved control of viral replication and slower disease progression among HIV-infected individuals.
5. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
6. Mellors JW, Margolick JB, Phair JP, et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 2007; 297:2349-2350. This study suggested that the slope of CD4+ T cell decline is an imprecise correlate of the rate of progression to AIDS in HIV-infected individuals, arguing against its use as a surrogate outcome in genetic association studies.
7. Madec Y, Boufassa F, Porter K, et al. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 2005; 19:2001-2007.
8. Greenough TC, Sullivan JL, Desrosiers RC. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med 1999; 340:236-237.
9. Hunt PW, Brenchley JM, Sinclair E, et al. Relationship between T cell activation and CD4 count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in absence of therapy. J Infect Dis (in press). This study demonstrated that even HIV-infected patients maintaining undetectable plasma HIV RNA levels in the absence of therapy may experience CD4+ T cell decline and disease progression in the setting of abnormally high generalized T cell activation levels, suggesting that factors independent of the control of viral replication contribute to disease progression.
10. Choudhary SK, Vrisekoop N, Jansen CA, et al. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in longterm asymptomatic disease. J Virol 2007; 81:8838-8842. This study demonstrated that some HIV-infected patients with high plasma HIV RNA levels may maintain low T cell activation levels and normal CD4+T cell counts in the absence of therapy, suggesting that factors independent of the level of viral replication contribute to disease progression.
11. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-1506.
12. Klein MR, Keet IP, D'Amaro J, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis 1994; 169:1244-1249.
13. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-411.
14. Costello C, Tang J, Rivers C, et al. HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS 1999; 13:1990-1991.
15. Gao X, Bashirova A, Iversen AK, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005; 11:1290-1292.
16. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-775.
17. Altfeld M, Addo MM, Rosenberg ES, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003; 17:2581-2591.
18. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:2709-2714.
19. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053-1056.
20. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006; 80:3617-3623.
21. Leslie AJ, Pfafferott KJ, Chetty P, et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004; 10:282-289.
22. Migueles SA, Laborico AC, Imamichi H, et al. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J Virol 2003; 77:6889-6898.
23. Bailey JR, Williams TM, Siliciano RF, et al. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med 2006; 203:1357-1369.
24. Qi Y, Martin MP, Gao X, et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog 2006; 2:e79. This study suggested that an activating KIR in the presence of its cognate HLA allele not only delays clinical progression to AIDS, but also protects against specific opportunistic infections, suggesting an independent role of natural killer cells in the control of other HIV-associated opportunistic infections.
25. Gaudieri S, DeSantis D, McKinnon E, et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005; 6:683-690.
26. Barbour JD, Sriram U, Caillier SJ, et al. Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog 2007; 3:e43.
27. Alter G, Martin MP, Teigen N, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007; 204:3027-3036. This study demonstrated that the interaction between KIR 3DS1 and HLA Bw4-80I observed in genetic association studies is associated with enhanced natural killer cell-mediated killing in vitro.
28. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-342.
29. Fernandez NC, Treiner E, Vance RE, et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005; 105:4416-4423.
30. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436:709-713.
31. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol 2006; 6:520-531.
32. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity 2006; 24:249-257.
33. Stranger BE, Forrest MS, Clark AG, et al. Genome-wide associations of gene expression variation in humans. PLoS Genet 2005; 1:e78.
34. Goulder PJ, Bunce M, Luzzi G, et al. Potential underestimation of HLA-C-restricted cytotoxic T-lymphocyte responses. AIDS 1997; 11:1884-1886.
35. Adnan S, Balamurugan A, Trocha A, et al. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood 2006; 108:3414-3419.
36. Jennes W, Verheyden S, Demanet C, et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006; 177:6588-6592. This study suggested a potential role of HLA-C alleles in the control of HIV replication via KIR-mediated modification of natural killer cell function.
37. Ravet S, Scott-Algara D, Bonnet E, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109:4296-4305. This study suggested a potential role of HLA-C alleles in the control of HIV replication via KIR-mediated modicification of NK cell function.
38. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol 2005; 5:835-843.
39. Fonteneau JF, Larsson M, Beignon AS, et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004; 78:5223-5232.
40. Herbeuval JP, Boasso A, Grivel JC, et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005; 105:2458-2464.
41. Herbeuval JP, Hardy AW, Boasso A, et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2005; 102:13974-13979.
42. Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003; 18:441-452.
43. Staprans S, Barry A, Klucking S, et al. Functional differences in dendritic-cell populations provide clues to the determinants of divergent disease outcomes following SIV infection of natural and nonnatural host species [abstract]. In: Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 22-25 February 2005; Boston. Alexandria: CROI; 2005. Abstract 152.
44. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862.
45. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
46. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
47. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-890.
48. Eugen-Olsen J, Iversen AK, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11:305-310.
49. Meyer L, Magierowska M, Hubert JB, et al. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS 1997; 11:F73-F78.
50. Michael NL, Louie LG, Rohrbaugh AL, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997; 3:1160-1162.
51. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998; 4:786-793.
52. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 30A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782-795.
53. Dolan MJ, Kulkarni H, Camargo JF, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8:1324-1336. This study demonstrated that genotypes associated with low CCR5 expression and high expression of its natural ligand delay disease progression in HIV-infected individuals independent of their effects on viral replication and improve responses to immunogens in HIV-uninfected individuals, suggesting a role for CCR5 blockade as an immune-based therapy.
54. Gosling J, Monteclaro FS, Atchison RE, et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc Natl Acad Sci U S A 1997; 94:5061-5066.
55. Davis CB, Dikic I, Unutmaz D, et al. Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 1997; 186:1793-1798.
56. Veazey R, Ling B, Pandrea I, et al. Decreased CCR5 expression on CD4+ T cells of SIV-infected sooty mangabeys. AIDS Res Hum Retroviruses 2003; 19:227-233.
57. Pandrea I, Apetrei C, Gordon S, et al. Paucity of CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood 2007; 109:1069-1076.
58. Mayer H, Ryst E, Saag M, et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial [abstract]. In: XVI International AIDS Conference; 13-18 August 2006; Toronto. Geneva: IAS; 2006.